At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
RO7049389 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Placebo-Controlled, Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Subjects
In Brief
A Phase 1 clinical trial evaluating RO7049389 and Placebo for Hepatitis B Virus. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This study will assess the safety and tolerability of RO7049389 compared to placebo in single- and multiple-ascending doses in healthy Chinese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B Virus
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartAug 2018
Primary CompletionJan 2019
TodayJul 2026
First PostedJun 27, 2018
Enrollment StartAug 24, 2018
Primary CompletionJan 28, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.0 years ago
Interventions
RO7049389drug
RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
Placebodrug
Placebo will be administered orally at a dose and frequency matched to RO7049389.